Unique Metabolism of a Novel Antiviral l -Nucleoside Analog, 2′-Fluoro-5-Methyl-β- l -Arabinofuranosyluracil: a Substrate for Both Thymidine Kinase and Deoxycytidine Kinase

Publisher Website
Google Scholar
Abstract
2′-Fluoro-5-methyl-β- l -arabinofuranosyluracil ( l -FMAU) is the first l -nucleoside analog with low cytotoxicity discovered to have potent antiviral activities against both hepatitis B virus and Epstein-Barr virus but not human immunodeficiency virus. This spectrum of activity is different from those of the other l -nucleoside analogs examined. l -FMAU enters cells through equilibrative-sensitive and -insensitive nucleoside transport as well as through nonfacilitated passive diffusion. l -FMAU is phosphorylated stepwise in cells to its mono-, di-, and triphosphate forms. In the present study the enzymes responsible for the first step of l -FMAU phosphorylation were identified. This is the first thymidine analog shown to be a substrate not only for cytosolic thymidine kinase and mitochondrial deoxypyrimidine kinase but also for deoxycytidine kinase. This finding suggests that the antiviral activity of l -FMAU will not be limited by the loss or alteration of any of these deoxynucleoside kinases.

This publication has 27 references indexed in Scilit: